Target intelligence / Profile preview

ATP synthase (F₁F₀-ATP synthase) (ATP synthase)

Target
ATP synthase
Molecular classification
Enzyme (ATP synthase, dehydrogenases), Multi-subunit protein complex (F₁F₀ ATP synthase), Oxidoreductase (electron transport chain enzymes, e.g., NADH dehydrogenase, cytochrome oxidases)
01

Overview

ATP synthase (F₁F₀-ATP synthase) is the core enzyme responsible for ATP production in mycobacteria by utilizing the proton motive force (PMF) generated through the electron transport chain (ETC) during oxidative phosphorylation[1][3][8]. Key ETC components include NADH dehydrogenases (NDH-1, NDH-2), succinate dehydrogenase (SDH), menaquinone, cytochrome complexes, and fumarate reductase, supporting aerobic and anaerobic energy metabolism[1][3][7]. Mycobacteria are remarkable for their metabolic flexibility, especially adaptation to hypoxia and nutrient shifts, mediated via complex regulatory networks and metabolic remodeling[2][7]. Drugs such as bedaquiline and Q203 selectively inhibit mycobacterial energy metabolism, making ATP synthase and ETC enzymes prime targets for tuberculosis therapy[1][8]. In summary, "Mycobacterial energy production" should be mapped to specific molecular targets (primarily ATP synthase and select electron transport chain enzymes) for therapeutic and scientific purposes[1][8][3].

Other names
F₁F₀ ATP synthaseFF-ATP synthaseMycobacterial electron transport chainMycobacterial ETC
02

Mechanism of action

Inhibition of ATP synthase (inhibiting conversion of PMF to ATP by bedaquiline) Disruption of electron transport chain (Q203 inhibition of cytochrome bc₁, thioridazine, phenothiazines block NDH-2, SDH) Dissipation of proton motive force (by ionophores, some antibiotics) Depletion of ATP pool

03

Biological functions

Energy metabolismATP synthesisMaintenance of membrane potentialAdaptation to hypoxiaRedox regulation
04

Disease associations

Infection (primarily tuberculosis and other mycobacterial diseases)
05

Safety considerations

Potential off-target effects on human mitochondrial ATP synthase (leading to cardiac and hepatic toxicity)Emergence of resistance (especially with bedaquiline)Drug-drug interactions, e.g., when combining respiratory inhibitors
06

Interacting drugs

Bedaquiline

4 more in the full profile.

07

Biomarkers

ATP levels in mycobacteria (for efficacy monitoring)Gene expression of atpD, nuo, ndh, sdh under drug exposure or energy stress

Beyond the preview

Go deeper on ATP synthase (F₁F₀-ATP synthase) (ATP synthase).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP synthase (F₁F₀-ATP synthase) (ATP synthase).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call